Consumer Perspectives on Genetic Testing for Psychiatric Disorders: The Attitudes of Veterans with Posttraumatic Stress Disorder and Their Families

Dedert, Eric A.; Elbogen, Eric B.; Hauser, Michael A.; Hertzberg, Jeff S.; Wilson, Sarah M.; Dennis, Michelle F.; Calhoun, Patrick S.; Kirby, Angela C.; Beckham, Jean C.

doi:10.1089/gtmb.2012.0048

Cited by 5 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Randomized 16 participants. To recruit a target population for intervention study Other Brown, Strauss, et al, 2014 Compared 68 subjects with PTSD and 60 trauma-exposed non-PTSD controls. Purpose was to evaluate effects of study procedures involving exposure to aversive stimuli on participation distress. Part of recruitment study evaluating target population Dedert et al, 2012 Compared 76 veterans with PTSD and 70 without PTSD. Purpose was to evaluate attitudes toward genetic research in PTSD. Part of a 3-year longitudinal follow-up study …”

Section: Table A1mentioning

confidence: 99%

The Post‐Deployment Mental Health (PDMH) study and repository: A multi‐site study of US Afghanistan and Iraq era veterans

Brancu

Wagner

Morey

et al. 2017

Int J Methods Psych Res

Self Cite

View full text Add to dashboard Cite

The United States (US) Department of Veterans Affairs (VA) Mid-Atlantic Mental Illness Research, Education, and Clinical Center (MIRECC) Post-Deployment Mental Health (PDMH) multi-site study examines post-deployment mental health in US military Afghanistan/Iraq-era veterans. The study includes the comprehensive behavioral health characterization of over 3600 study participants and the genetic, metabolomic, neurocognitive, and neuroimaging data for many of the participants. The study design also incorporates an infrastructure for a data repository to re-contact participants for follow-up studies. The overwhelming majority (94%) of participants consented to be re-contacted for future studies, and our recently completed feasibility study indicates that 73-83% of these participants could be reached successfully for enrollment into longitudinal follow-up investigations. Longitudinal concurrent cohort follow-up studies will be conducted (5-10+ years post-baseline) to examine predictors of illness chronicity, resilience, recovery, functional outcome, and other variables, and will include neuroimaging, genetic/epigenetic, serum biomarker, and neurocognitive studies, among others. To date, the PDMH study has generated more than 35 publications from the baseline data and the repository has been leveraged in over 20 publications from follow-up studies drawing from this cohort. Limitations that may affect data collection for a longitudinal follow-up study are also presented.

show abstract

Section: Table A1mentioning

confidence: 99%

The Post‐Deployment Mental Health (PDMH) study and repository: A multi‐site study of US Afghanistan and Iraq era veterans

Brancu

Wagner

Morey

et al. 2017

Int J Methods Psych Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…This may lead to an ambivalent view in the society towards genetic testing. PTSD patients are less ready to agree with genetic testing of their family members [ 188 ]. Furthermore, genetic poly- morphisms are differently distributed among the human populations on earth.…”

Section: Studies On Genetic Polymorphisms Among Military Personnelmentioning

confidence: 99%

Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder

Naß

Efferth

2017

View full text Add to dashboard Cite

Background:Posttraumatic stress disorder (PTSD) is a severe problem among soldiers with combating experience difficult to treat. The pathogenesis is still not fully understood at the psychological level. Therefore, genetic research became a focus of interest. The identification of single nucleotide polymorphisms (SNPs) may help to predict, which persons are at high risk to develop PTSD as a starting point to develop novel targeted drugs for treatment.Methods:We conducted a systematic review on SNPs in genes related to PTSD pathology and development of targeted pharmacological treatment options based on PubMed database searches. We focused on clinical trials with military personnel.Results:SNPs in 22 human genes have been linked to PTSD. These genes encode proteins acting as neurotransmitters and receptors, downstream signal transducers and metabolizing enzymes. Pharmacological inhibitors may serve as drug candidates for PTSD treatment, e.g. β2 adrenoreceptor antagonists, dopamine antagonists, partial dopamine D2 receptor agonists, dopamine β hydroxylase inhibitors, fatty acid amid hydrolase antagonists, glucocorticoid receptor agonists, tropomyosin receptor kinase B agonists, selective serotonin reuptake inhibitors, catechol-O-methyltransferase inhibitors, gamma-amino butyric acid receptor agonists, glutamate receptor inhibitors, monoaminoxidase B inhibitors, N-methyl-d-aspartate receptor antagonists.Conclusion:The combination of genetic and pharmacological research may lead to novel target-based drug developments with improved specificity and efficacy to treat PTSD. Specific SNPs may be identified as reliable biomarkers to assess individual disease risk. Focusing on soldiers suffering from PTSD will not only help to improve treatment options for this specific group, but for all PTSD patients and the general population.

show abstract

“…Only one study to date has evaluated veterans’ attitudes toward psychiatric disorder genetic testing (7). This study found that veterans with posttraumatic stress disorder (PTSD) viewed genetic testing for PTSD less favorably than those without PTSD and were more likely to fear insurance discrimination.…”

Section: Introductionmentioning

confidence: 99%

“…A review of studies on general consumer attitudes surrounding genetic testing for psychiatric disorders identified several areas for future study: specifically, the need to study individuals without psychiatric disorders or not involved in genetics-related research, and the need for larger samples ( 2 ). Only one study to date has evaluated veterans’ attitudes toward psychiatric disorder genetic testing ( 7 ). This study found that veterans with posttraumatic stress disorder (PTSD) viewed genetic testing for PTSD less favorably than those without PTSD and were more likely to fear insurance discrimination.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Attitudes about Future Genetic Testing for Posttraumatic Stress Disorder and Addiction among Community-Based Veterans

et al. 2017

View full text Add to dashboard Cite

This study explored attitudes toward hypothetical genetic testing for posttraumatic stress disorder (PTSD) and addiction among veterans. We surveyed a random sample of community-based veterans (n = 700) by telephone. One year later, we asked the veterans to provide a DNA sample for analysis and 41.9% of them returned the DNA samples. Overall, most veterans were not interested in genetic testing neither for PTSD (61.7%) nor for addiction (68.7%). However, bivariate analyses suggested there was an association between having the condition of interest and the likelihood of genetic testing on a 5-point scale (p < 0.001 for PTSD; p = 0.001 for alcohol dependence). While ordinal regressions confirmed these associations, the models with the best statistical fit were bivariate models of whether the veteran would likely test or not. Using logistic regressions, significant predictors for PTSD testing were receiving recent mental health treatment, history of a concussion, younger age, having PTSD, having alcohol dependence, currently taking opioids for pain, and returning the DNA sample during the follow-up. For addiction testing, significant predictors were history of concussion, younger age, psychotropic medication use, having alcohol dependence, and currently taking opioids for pain. Altogether, 25.9% of veterans reported that they would have liked to have known their genetic results before deployment, 15.6% reported after deployment, and 58.6% reported they did not want to know neither before nor after deployment. As advancements in genetic testing continue to evolve, our study suggests that consumer attitudes toward genetic testing for mental disorders are complex and better understanding of these attitudes and beliefs will be crucial to successfully promote utilization.

show abstract

Consumer Perspectives on Genetic Testing for Psychiatric Disorders: The Attitudes of Veterans with Posttraumatic Stress Disorder and Their Families

Cited by 5 publications

References 35 publications

The Post‐Deployment Mental Health (PDMH) study and repository: A multi‐site study of US Afghanistan and Iraq era veterans

The Post‐Deployment Mental Health (PDMH) study and repository: A multi‐site study of US Afghanistan and Iraq era veterans

Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder

Attitudes about Future Genetic Testing for Posttraumatic Stress Disorder and Addiction among Community-Based Veterans

Contact Info

Product

Resources

About